These findings highlight pharmacological activation of the HDAC1/TAF9 pathway as an attractive approach to alleviate NAFLD and identify DSS as a new candidate for NAFLD therapy. Here, HDAC1 is linked to metabolic dysfunction-associated steatotic liver disease.